RZLT is trading at $4.93 (5% down) today, extending its recent decline as negative sentiment persists following the failed Phase 3 trial of its hypoglycemia drug, ersodetug.
- The stock previously saw an 80–90% collapse and significant price target cuts after the pivotal study failed to meet its primary endpoints.
- Today's move appears driven by a continuation of trial-related weakness and negative biotech sentiment rather than new company-specific catalysts.
- The decline stands out against relatively flat major indices, highlighting the ongoing pressure on the stock's valuation following the clinical setback.